Trust Co. of Toledo NA OH Has $501,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Trust Co. of Toledo NA OH boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,651 shares of the company’s stock after buying an additional 337 shares during the period. Trust Co. of Toledo NA OH’s holdings in AstraZeneca were worth $501,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AZN. Bank of Montreal Can raised its holdings in AstraZeneca by 109.6% during the 3rd quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after buying an additional 1,605,758 shares during the period. Franklin Resources Inc. grew its stake in AstraZeneca by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after acquiring an additional 1,522,715 shares in the last quarter. Hsbc Holdings PLC grew its stake in AstraZeneca by 750.3% during the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after acquiring an additional 1,132,362 shares in the last quarter. Farallon Capital Management LLC grew its stake in AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after acquiring an additional 950,000 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in AstraZeneca during the 3rd quarter valued at about $72,437,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 1.9 %

Shares of NASDAQ AZN opened at $65.73 on Tuesday. The stock has a market cap of $203.80 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 1.19 and a beta of 0.46. The business has a 50 day simple moving average of $66.00 and a 200 day simple moving average of $74.78. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.87 EPS. On average, research analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.